iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring
The Zio LTCM service consists of a prescription-only, patch-based ECG monitoring device that captures up to 14 days of continuous, uninterrupted data, and the ZEUS® (Zio ECG Utilization Software) system with an FDA-cleared AI algorithm clinically proven to perform at the level of cardiologists.1 The system delivers an end-of-wear report that is reviewed and validated by qualified cardiac technicians, with a 99% physician agreement rate.2 Building on findings from the CAMELOT (Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events) study—published in the American Heart Journal—which demonstrated the clinical superiority of the Zio LTCM service among a Medicare population, the AVALON study evaluated a younger, commercially insured population (mean age: 46 years).
Across the providers in the LTCM space, Bardy, BioTelemetry, Preventice, and "Other LTCM” providers were associated, respectively, as 1.41, 1.39, 1.30, and 3.52 times more likely to result in a retest within 180 days compared to Zio LTCM.3 Zio LTCM service was associated with lowest adjusted odds of cardiovascular events within 1-year compared to ACM modalities and all other LTCMs from service providers in the same extended monitoring category.Holter monitors were 1.13 times more likely and AEM were 1.21 times more likely to have a CV event within 1-year compared to Zio LTCM service.
SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc.(NASDAQ:IRTC) announced results from a large real-world retrospective analysis presented at the Heart Rhythm Society’s annual meeting, HRS2025, held April 24–27 in San Diego, CA, The Assessment of Variation in AmbuLatory Cardiac MONitoring: Real-World Evidence of Commercially Insured Beneficiaries (AVALON) study—drawing on claims data from a cohort of 428,707 commercially insured patients—represents the largest real-world comparative evaluation of ambulatory cardiac monitoring (ACM) among this population to date, and reinforces the clinical superiority of the Zio® long-term continuous monitoring (LTCM) service.
The story "iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring" has 1978 words across 66 sentences, which will take approximately 9 - 17 minutes for the average person to read.
Which news outlet covered this story?
The story "iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring" was covered 1 days ago by GlobeNewswire, a news publisher based in China.
How trustworthy is 'GlobeNewswire' news outlet?
GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.
The outlet is headquartered in China and publishes an average of 117 news stories per day.
It's most recent story was published 9 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Negative, indicating that people regard this as "bad news".
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
